Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Biochem Pharmacol. 2020 Jul 16;189:114154. doi: 10.1016/j.bcp.2020.114154

Table 3.

IPA curated 38 of 60 miRNAs known to be involved in cancer drug resistance by efflux pathway. MiRNAs in bold represent four of the top five miRNAs experimentally validated to promote erlotinib resistance from Table 1.

MiRNAs involved in cancer drug resistance by efflux pathway
hsa-miR-204-3p
hsa-miR-3198
hsa-miR-3618
hsa-miR-432-5p
hsa-miR-4328
hsa-miR-4329
hsa-miR-4435
hsa-miR-4468
hsa-miR-4488
hsa-miR-4499
hsa-miR-4516
hsa-miR-4521
hsa-miR-4522
hsa-miR-4534
hsa-miR-4638-3p
hsa-miR-4654
hsa-miR-4661-3p
hsa-miR-4690-3p
hsa-miR-4693-5p
hsa-miR-4706
hsa-miR-4728-5p
hsa-miR-4740-3p
hsa-miR-4741
hsa-miR-4751
hsa-miR-4753-3p
hsa-miR-4757-5p
hsa-miR-4778-5p
hsa-miR-4781-3p
hsa-miR-4787-5p
hsa-miR-4792
hsa-miR-4793-5p
hsa-miR-4794
hsa-miR-548ab
hsa-miR-548ac
hsa-miR-548aj-3p
hsa-miR-5693
hsa-miR-5694
hsa-miR-9-5p